Loading...
XKRX003090
Market cap588mUSD
Dec 24, Last price  
20,950.00KRW
1D
-0.95%
1Q
-16.37%
Jan 2017
137.80%
Name

Daewoong Co Ltd

Chart & Performance

D1W1MN
XKRX:003090 chart
P/E
5.61
P/S
0.47
EPS
3,733.49
Div Yield, %
0.95%
Shrs. gr., 5y
-0.85%
Rev. gr., 5y
8.07%
Revenues
1.82t
+6.94%
500,880,459,000607,247,194,000695,010,620,000766,644,083,000670,825,226,000270,641,226,890306,154,896,540843,534,264,430893,976,778,700996,645,900,6501,015,010,730,4701,124,075,727,1401,231,173,935,6601,365,679,369,3301,355,337,386,7501,511,373,580,8101,697,338,482,5801,815,103,675,124
Net income
152.67b
+48.85%
24,284,888,00029,629,972,00015,878,328,00020,011,814,00032,363,158,00043,268,255,00044,199,500,18040,771,653,96023,811,158,08038,623,412,96019,831,075,11066,250,630,10029,863,274,89062,439,349,48098,378,893,02078,730,194,980102,565,588,550152,665,121,740
CFO
205.65b
+37.95%
52,235,463,00041,661,606,00056,712,968,000118,036,604,00034,417,099,00010,404,679,58027,615,344,38086,193,904,77046,607,316,99074,916,093,23018,755,841,540147,774,279,09045,380,803,380138,512,224,900145,365,812,640133,175,353,200149,081,680,740205,654,597,630
Dividend
Dec 27, 2023100 KRW/sh
Earnings
Feb 10, 2025

Profile

Daewoong Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals. It also engages in the leasing of real estates. The company was formerly known as Daewoong Pharmaceutical Co., Ltd. and changed its name to Daewoong Co., Ltd. in 2002. Daewoong Co., Ltd. was founded in 1961 and is headquartered in Seongnam-si, South Korea.
URL
http://www.daewoongholdings.com/
IPO date
Jun 26, 1973
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,815,103,675
6.94%
1,697,338,483
12.30%
1,511,373,581
11.51%
Cost of revenue
1,436,163,903
1,308,778,381
1,173,190,307
Unusual Expense (Income)
NOPBT
378,939,772
388,560,102
338,183,274
NOPBT Margin
20.88%
22.89%
22.38%
Operating Taxes
11,083,066
34,664,176
13,427,079
Tax Rate
2.92%
8.92%
3.97%
NOPAT
367,856,706
353,895,926
324,756,195
Net income
152,665,122
48.85%
102,565,589
30.27%
78,730,195
-19.97%
Dividends
(8,119,145)
(4,156,569)
(4,246,919)
Dividend yield
0.95%
0.49%
0.33%
Proceeds from repurchase of equity
(9,908,541)
174,631
143,829,832
BB yield
1.16%
-0.02%
-11.15%
Debt
Debt current
381,763,137
234,819,026
257,136,452
Long-term debt
70,994,216
212,875,965
193,597,808
Deferred revenue
36,403,016
36,933,145
Other long-term liabilities
164,390,921
95,069,791
22,267,736
Net debt
(170,098,077)
87,620,111
183,577,233
Cash flow
Cash from operating activities
205,654,598
149,081,681
133,175,353
CAPEX
(181,443,241)
(117,622,887)
(115,508,732)
Cash from investing activities
(204,815,148)
(105,493,345)
(219,131,313)
Cash from financing activities
(28,983,853)
22,571,774
10,997,099
FCF
228,550,559
257,684,782
331,296,750
Balance
Cash
267,163,536
386,740,192
387,853,398
Long term investments
355,691,893
(26,665,312)
(120,696,371)
Excess cash
532,100,245
275,207,955
191,588,348
Stockholders' equity
1,143,077,752
1,407,678,113
1,241,130,831
Invested Capital
1,517,935,650
1,551,298,157
1,442,482,917
ROIC
23.97%
23.64%
23.97%
ROCE
18.48%
21.02%
20.51%
EV
Common stock shares outstanding
41,354
41,577
41,553
Price
20,650.00
1.47%
20,350.00
-34.46%
31,050.00
-38.27%
Market cap
853,956,755
0.93%
846,093,354
-34.42%
1,290,225,866
-38.91%
EV
1,185,861,327
1,384,380,566
1,900,280,068
EBITDA
433,160,957
436,839,581
388,741,080
EV/EBITDA
2.74
3.17
4.89
Interest
13,993,951
8,351,007
10,292,225
Interest/NOPBT
3.69%
2.15%
3.04%